Literature DB >> 19396552

Plasma homocysteine is adversely associated with glomerular filtration rate in asymptomatic black and white young adults: the Bogalusa heart study.

Litao Ruan1, Wei Chen, Sathanur R Srinivasan, Jihua Xu, Ahmet Toprak, Gerald S Berenson.   

Abstract

That plasma homocysteine is elevated markedly in renal dysfunction is well recognized. But whether the increased homocysteine is an independent correlate of glomerular filtration rate, a marker of renal function, in asymptomatic younger individuals is not clear. The aim of this study was to determine the association between plasma homocysteine and renal function in a biracial (black-white) community-based cohort of asymptomatic young adults. Plasma homocysteine along with cardiovascular disease risk factor variables were measured in 805 white and 330 black subjects, ages 24-44 years, enrolled in the Bogalusa Heart Study. Modification of Diet in Renal Disease Study equation was used to calculate the estimated glomerular filtration rate (eGFR) from serum creatinine level. Males versus females showed higher homocysteine levels (8.83 +/- 3.16 vs. 7.35 +/- 2.84 micromol/L, p < 0.0001) and lower eGFR (99.1 +/- 17.6 vs. 102.5 +/- 21.0 mL/min/1.73 m(2), p = 0.024). Whites versus blacks had lower eGFR (97.3 +/- 18.0 vs. 110.0 +/- 20.6 mL/min/1.73 m(2), p < 0.0001). In a multivariate regression analysis that included age, race, sex, body mass index, blood pressure, lipoprotein variables, insulin resistance index and homocysteine, white race, age and homocysteine, in that order, were independently and negatively associated with eGFR. The odds ratio (95% confidence interval) of individuals in the homocysteine quintiles II, III, IV and V vs. I for having the risk of impaired eGFR defined as <10th percentile was 2.28 (0.95-5.50, p = 0.065), 2.97 (1.24-7.12, p = 0.015), 3.32 (1.45-7.60, p = 0.005) and 6.99 (3.06-15.94, p < 0.0001), respectively. Homocysteine is an independent correlate of renal function in asymptomatic black and white young adults.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396552     DOI: 10.1007/s10654-009-9340-0

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  35 in total

1.  Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study.

Authors:  A Jager; P J Kostense; G Nijpels; J M Dekker; R J Heine; L M Bouter; A J Donker; C D Stehouwer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-01       Impact factor: 8.311

Review 2.  Hyperhomocysteinemia in chronic renal disease.

Authors:  A G Bostom; B F Culleton
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

Review 3.  Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes.

Authors:  A G Bostom; L Lathrop
Journal:  Kidney Int       Date:  1997-07       Impact factor: 10.612

4.  Homocysteine, traditional risk factors and impaired renal function in coronary artery disease.

Authors:  F Pizzolo; S Friso; O Olivieri; N Martinelli; C Bozzini; P Guarini; E Trabetti; G Faccini; R Corrocher; D Girelli
Journal:  Eur J Clin Invest       Date:  2006-10       Impact factor: 4.686

5.  Plasma homocysteine concentrations in young individuals at increased risk of type 2 diabetes are associated with subtle differences in glomerular filtration rate but not with insulin resistance.

Authors:  S A Schäfer; K Müssig; N Stefan; H-U Häring; A Fritsche; B M Balletshofer
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-06       Impact factor: 2.949

6.  Positive association between plasma homocysteine level and chronic kidney disease.

Authors:  Anoop Shankar; Jie Jin Wang; Brian Chua; Elena Rochtchina; Vicki Flood; Paul Mitchell
Journal:  Kidney Blood Press Res       Date:  2008-01-30       Impact factor: 2.687

7.  Homocysteinemia in hypertensive patients with renal target organ damage (mild renal dysfunction).

Authors:  N R Robles; J F Sanchez Munoz-Torrero; F Garcia Gallego; J Velasco Gemio; J M Escola
Journal:  Eur J Med Res       Date:  2008-05-26       Impact factor: 2.175

Review 8.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

9.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

10.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

Authors:  P F Jacques; A G Bostom; R R Williams; R C Ellison; J H Eckfeldt; I H Rosenberg; J Selhub; R Rozen
Journal:  Circulation       Date:  1996-01-01       Impact factor: 29.690

View more
  14 in total

1.  The Shanghai Changfeng Study: a community-based prospective cohort study of chronic diseases among middle-aged and elderly: objectives and design.

Authors:  Xin Gao; Albert Hofman; Yu Hu; Huandong Lin; Chouwen Zhu; Johannes Jeekel; Xuejuan Jin; Jiyao Wang; Jian Gao; Yiqing Yin; Naiqing Zhao
Journal:  Eur J Epidemiol       Date:  2010-12-01       Impact factor: 8.082

2.  Association between plasma homocysteine status and hypothyroidism: a meta-analysis.

Authors:  Yande Zhou; Yufang Chen; Xueqin Cao; Chunfeng Liu; Ying Xie
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  Prevalence of hyperhomocysteinemia (HHcy) and its major determinants among hypertensive patients over 35 years of age.

Authors:  Minna Cheng; Hong Xue; Xinjian Li; Qinghua Yan; Dingliang Zhu; Yan Wang; Yan Shi; Chen Fu
Journal:  Eur J Clin Nutr       Date:  2021-08-30       Impact factor: 4.016

4.  Homocysteine as a risk factor for development of microalbuminuria in type 2 diabetes.

Authors:  Eun-Hee Cho; Eun Hee Kim; Won Gu Kim; Eun Hui Jeong; Eun Hee Koh; Woo-Je Lee; Min-Seon Kim; Joong-Yeol Park; Ki-Up Lee
Journal:  Korean Diabetes J       Date:  2010-06-30

5.  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe Efstathiadou; Ioannis Litsas; Marina Kita; Athanasios Panagiotou; Athanasios Papatheodorou; Georgios Arsos; Efstratios Moralidis; Georgios Barmpalios; Efthimia Zafeiriadou; Efthimia Triantafillidou; Eleni Makrigiannaki; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2009-10-21       Impact factor: 2.626

6.  Association of homocysteine with type 1 diabetes mellitus: a meta-analysis.

Authors:  Yu Feng; Mei-Qin Shan; Lin Bo; Xiao-Yan Zhang; Ji Hu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  Methylenetetrahydrofolate reductase C677T polymorphism is associated with estimated glomerular filtration rate in hypertensive Chinese males.

Authors:  Qing Dong; Genfu Tang; Mingli He; Yunqing Cai; Yefeng Cai; Houxun Xing; Liming Sun; Jianping Li; Yan Zhang; Fangfang Fan; Binyan Wang; Ningling Sun; Lisheng Liu; Xiping Xu; Fanfan Hou; Hongbing Shen; Xin Xu; Yong Huo
Journal:  BMC Med Genet       Date:  2012-08-16       Impact factor: 2.103

8.  New studies, technology, and the progress of epidemiology.

Authors:  Albert Hofman
Journal:  Eur J Epidemiol       Date:  2010-12       Impact factor: 8.082

9.  The Generation R Study: design and cohort update 2010.

Authors:  Vincent W V Jaddoe; Cock M van Duijn; Albert J van der Heijden; Johan P Mackenbach; Henriëtte A Moll; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2010-10-22       Impact factor: 8.082

10.  The Rotterdam Study: 2012 objectives and design update.

Authors:  Albert Hofman; Cornelia M van Duijn; Oscar H Franco; M Arfan Ikram; Harry L A Janssen; Caroline C W Klaver; Ernst J Kuipers; Tamar E C Nijsten; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2011-08-30       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.